Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a
dermatology therapeutics company developing medications for skin
diseases requiring medical interventions, today announced that Ted
White, Verrica President and CEO, will present a business overview
at the H.C. Wainwright Annual Global Life Sciences Conference,
taking place March 9-10, 2021.
A pre-recorded presentation will be available for on-demand
access beginning at 7:00 a.m. ET on Tuesday, March 9, 2021.
Participants may access a webcast of the event through the
The webcast can also be accessed in the Investors/Presentations
& Events section of the Verrica website at www.verrica.com. The
webcast replay will be available shortly after conclusion of the
event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing
medications for skin diseases requiring medical interventions.
Verrica’s late-stage product candidate, VP-102, is in development
to treat molluscum, common warts and external genital warts, three
of the largest unmet needs in medical dermatology. Verrica is also
developing VP-103, its second cantharidin-based product candidate,
for the treatment of plantar warts. The Company has also entered a
worldwide license agreement with Lytix Biopharma AS to develop and
commercialize LTX-315 for dermatologic oncology conditions. For
more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
A. Brian DavisChief Financial
Officer484.453.3300 ext. email@example.com